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Summary
Background: Previous studies have demonstrated re-
expression of cell-cycle markers within postmitotic neu-
rons in neurodegenerative tauopathies, including Alz-
heimer’s disease (AD). However, the critical questions
of whether cell-cycle activation is causal or epiphenom-
enal to tau-induced neurodegeneration and which sig-
naling pathways mediate cell-cycle activation in tauop-
athy remain unresolved.
Results: Cell-cycle activation accompanies wild-type
and mutant tau-induced neurodegeneration in Droso-
phila, and genetically interfering with cell-cycle prog-
ression substantially reduces neurodegeneration. Our
data support a role for cell-cycle activation downstream
of tau phosphorylation, directly preceding apoptosis.
We accordingly show that ectopic cell-cycle activation
leads to apoptosis of postmitotic neurons in vivo. As
in AD, TOR (target of rapamycin kinase) activity is
increased in our model and is required for neurodegen-
eration. TOR activation enhances tau-induced neurode-
generation in a cell cycle-dependent manner and, when
ectopically activated, drives cell-cycle activation and
apoptosis in postmitotic neurons.
Conclusions: TOR-mediated cell-cycle activation
causes neurodegeneration in a Drosophila tauopathy
model, identifying TOR and the cell cycle as potential
therapeutic targets in tauopathies and AD.
Introduction
AD and tauopathies are neurodegenerative diseases
characterized by abnormal accumulations of hyper-
phosphorylated tau, a microtubule-associated protein
[1]. While the discovery that dominant mutations in the
TAU gene cause hereditary frontotemporal dementias
has directly implicated tau in disease pathogenesis [2],
the mechanisms through which tau drives neurode-
generation remain elusive. Intriguingly, several stud-
ies have described aberrant neuronal expression and
*Correspondence: mel_feany@hms.harvard.edulocalization of cell-cycle proteins in postmortem tissue
from patients with tauopathies and AD [3]. Several pos-
itive regulators of the G1/S and G2/M cell-cycle transi-
tions are aberrantly expressed or localized, including
cyclins and cyclin-dependent kinases (Cdks) [4], the S-
phase marker proliferating cell nuclear antigen (PCNA
[5]), and the M-phase marker phosphohistone-3 (PH3
[6]). In addition, one study has demonstrated that neu-
rons in AD replicate their DNA prior to dying [7]. While
these findings raise the possibility that cell-cycle activa-
tion is deleterious for postmitotic neurons, two critical
issues remain unresolved. First, it has been unclear
whether there is a causal relationship in vivo between
cell-cycle activation and neurodegeneration [8]. The up-
regulation of negative cell-cycle regulators (including
p27kip/waf) in AD has further complicated the functional
relationship between cell-cycle activation and neurode-
generation [9]. Second, the signaling pathways mediat-
ing cell-cycle activation in neurodegenerative tauopa-
thies have not been determined. Neuronal markers for
several mitogenic signaling pathways are aberrantly up-
regulated in AD, including the target of rapamycin (TOR)
kinase pathway [10–12], a downstream effector of insu-
lin signaling known to regulate growth and lifespan [13,
14]. However, the significance of these pathways in dis-
ease has not been determined, nor whether their activa-
tion can lead to reactivation of cell cycle in postmitotic
neurons. Indeed, inconsistencies in the reported effects
of these pathways on neuronal survival in cell-culture
systems [15, 16] underscore the need for investigation
in an animal model [8].
Genetic analysis in Drosophila is well suited to ad-
dress the issue of causality. The relationship among
tau-induced neurodegeneration, cell-cycle activation,
and mitogenic signaling pathways in vivo can appropri-
ately be investigated in flies because, first, key features
of human tauopathies, including tau hyperphosphoryla-
tion and progressive neurodegeneration, are recapitu-
lated by transgenic expression of human or mutant
wild-type tau [17–19]. Second, fly and mammalian
cell-cycle machineries are substantially conserved, as
are mitogenic signaling pathways including the TOR
pathway [20]. In Drosophila, as in mammalian cells,
Rheb activates TOR and drives cells through the G1/S
cell-cycle transition, and Tsc proteins restrict tissue
growth and reduce cell size and cell proliferation by di-
rectly inhibiting Rheb. Activation of TOR signaling leads
to phosphorylation of S6k at Thr389 in mammalian
cells, and a recent study has shown this epitope is ele-
vated in AD tissue [10]. TOR activity can similarly be
measured in Drosophila by detecting phosphorylation
of S6k at Thr398, the corresponding site in the fly pro-
tein [20].
In this study we show that cell-cycle activation
accompanies wild-type and mutant tau-induced apo-
ptotic neurodegeneration in Drosophila. Genetic and
pharmacologic inhibition at both the G1/S and G2/M
cell-cycle transitions blocks neuronal apoptosis,
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231Figure 1. Cell-Cycle Activation Accompanies Neurodegeneration in 10-Day-Old TauR406W Transgenic Flies
(A and B) Hematoxylin and eosin-stained nontransgenic control fly brain demonstrating normal numbers and morphology of cortical neurons (A)
compared to tau transgenic fly in which neuronal vacuolization and nuclear fragmentation is seen (B, arrow).
(C–H) TUNEL (C and D), PCNA (E and F), and PH3 (G and H)-positive neurons are absent in controls (C, E, G) but are prominent in tau transgenics
(D, F, H), as indicated by arrows. A blue (hematoxylin) nuclear counterstain is used in (E) and (F). Scale bar equals 10 mm.establishing a clear causal relationship between cell-
cycle activation and tau-induced neurodegeneration.
Our data implicate cell-cycle activation downstream of
tau phosphorylation and directly preceding apoptosis.
Finally, as in human disease, TOR activity is upregu-
lated in our model. TOR is required for neurodegenera-
tion and, furthermore, drives cell-cycle activation in
postmitotic neurons and enhances tau-induced neuro-
degeneration in a cell cycle-dependent manner. Our re-
sults thus causally implicate cell-cycle activation in tau-
induced neurodegeneration and identify TOR signaling
as an important pathway through which tau activates
the cell cycle.
Results
Cell-Cycle Activation Accompanies
Neurodegeneration in a Drosophila Tauopathy
Model
We first determined whether cell-cycle activation ac-
companied neurodegeneration in a fly model of tauop-
athy. We have previously reported that expression of
a mutant form of tau linked to familial frontotemporal de-
mentia, tauR406W, in the fly brain (panneural driver:ELAV-
GAL4) leads to progressive neurodegeneration [17]. At
eclosion, the brains of tau-expressing flies appeared
morphologically normal, but by 10 days clear neurode-
generation was observed, characterized histologically
by condensation and fragmentation of neuronal nuclei
and vacuolization (Figures 1A and 1B). TUNEL staining
identified apoptotic neurons in tau transgenic animals
but not in age-matched controls (Figures 1C and 1D).
We immunostained for PCNA and PH3 to assess early
and late cell-cycle activation. Control animals were
completely negative for PCNA and PH3 at 10 days (Fig-
ures 1E and 1G) and 30 days (data not shown). In con-
trast, brains from tau transgenic flies showed prominent
expression of both PCNA (Figure 1F) and PH3
(Figure 1H) at 10 days. PCNA staining was particularly
prominent in areas of neurodegeneration, as indicated
by characteristic nuclear changes and cytoplasmic va-
cuolization (Figure 1F).
Together, these findings demonstrate that abnormal
activation of the cell cycle accompanies tau-induced ap-
optotic neurodegeneration in Drosophila and suggestthat cell-cycle activation is likely to be a relatively late
event in our model.
Cell-Cycle Activation Mediates Mutant Tau-Induced
Neurodegeneration
In flies, entry into the G1/S transition is coordinated by
the transcription factor E2F1/DP and Cdk2 complexed
to Cyclin E (Cdk2/Cyclin E; Figure 2A). Transgenic coex-
pression of the E2F1 inhibitor Retinoblastoma factor-1
(Rbf1) and the Cdk2 inhibitor Dacapo (Dap; the Dro-
sophila homolog of human p21/p27) synergistically
block the G1/S transition (Figure 2A; [21]). We coex-
pressed Dap and Rbf1 with tau in the fly brain and found
a significantly reduced number of TUNEL-positive cells
in the brain compared to age-matched tau transgenic
flies (Figure 2B). b-galactosidase (b-gal) was used to
control for nonspecific effects of expressing tau to-
gether with an additional transgene.
In Drosophila, Cdk1 (cdc2) and Cyclin A form a com-
plex (Cdk1/Cyclin A) that catalyzes the G2/M transition,
and Cdk1/Cyclin B is required for progression through
mitosis (Figure 2A). We found that the number of
TUNEL-positive cells was significantly reduced by coex-
pressing tau with Dap and Cdk1E51Q, a dominant-nega-
tive form of Cdk1 [22] (Cdk1DN; Figure 2B), and signifi-
cantly increased by coexpressing Cyclin A with tau
(Figure 2C). Cyclin A did not produce significant neuro-
degeneration when expressed alone (Figure 2C). Coex-
pression of Cyclin E or Cdk1/Cyclin B in the brain with
tau was lethal or semilethal, consistent with enhanced
toxicity. Coexpressing Cdk4/Cyclin D, which drives
growth and cell cycle in flies, was semilethal. Immuno-
blotting demonstrated equivalent tau protein levels in
10-day-old tau-expressing flies and flies coexpressing
tau with cell-cycle modifiers (not shown), indicating
that the genetic modification observed was not attribut-
able to altered tau expression. Expressing cell-cycle
modifiers in the brain without tau did not change gross
brain morphology or cellularity (not shown).
Cell-cycle modification of neurodegeneration was ap-
parent on routine histological analysis. In control flies,
the neuronal projections in the lamina appear as regular
longitudinal bundles in frontal sections (Figure 2E). The
lamina of 1-day-old flies expressing tau (Figure 2G),
tau together with Dap and Rbf1 (Figure 2I), or tau with
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(A) The cell-cycle machinery is highly conserved between Drosophila and mammalian cells.
(B–D) Genetic and pharmacologic cell-cycle modulation modifies neurodegeneration in transgenic tauR406W fly brains. Neurodegeneration is
suppressed by coexpressing Dap and Rbf1 or Dap and Cdk1DN (B) and enhanced by Cyclin A (C). Neurodegeneration is suppressed by feed-
ing the Cdk inhibitor drug olomoucine (D). Statistically significant differences from control groups are indicated (one-way ANOVA with Student-
Neuman-Keuls; *p < 0.05; ***p < 0.001). Error bars: 6 SEM.
(E–L) Cell-cycle modulation modifies tau-mediated degeneration in the lamina. Lamina structure is normal in control flies at 1 (E) and 10 (F) days
and in 1-day-old flies expressing tauR406W with b-gal (G), tauR406W with Dap and Rbf1 (I), or tauR406W with Cyclin A (K). Vacuolar degeneration in
flies coexpressing tauR406W with b-gal at 10 days (H, arrow) is suppressed by coexpressing tauR406W with Dap and Rbf1 (J) and enhanced by
coexpressing tauR406W with Cyclin A (L, arrow). Scale bar equals 10 mm.
(M–U) Cell-cycle modulation modifies the mutant tauV337M-induced rough-eye phenotype. Compare normal eye structure (M) to the tauV337M-in-
duced rough eye (N). The tauV337M-induced rough eye is strongly suppressed by coexpressing tauV337M with Dap and Rbf1 (O), Dap and Cdk1DN
(P), or by removing one copy of E2f1 (Q) orCyclin A (R). The tauV337M-induced retinal pathology is enhanced by coexpressing tauV337M with Cdk4/
Cyclin D (S), Cyclin B (T), or Cyclin A (U).Cyclin A (Figure 2K) exhibited regular organization.
While the lamina of 10-day-old control flies appeared
normal (Figure 2F), vacuolar degeneration of the lamina
occurred in tau flies aged to 10 days (Figure 2H). This de-
generation was rescued by coexpression of Dap and
Rbf1 (Figure 2J) and was strikingly enhanced by Cyclin
A (Figure 2L). Flies expressing Cyclin A alone did not ex-
hibit vacuolization (not shown).
These genetic data implied that cell-cycle activation
at both the G1/S and G2/M transitions contributes to
tau-induced neurodegeneration in vivo. We also found
that pharmacologic inhibition of the cell cycle amelio-
rated tau-induced neurodegeneration, because feeding
tau-expressing flies olomoucine reduced the number of
TUNEL-positive neurons significantly by 10 days
(Figure 2D). Olomoucine is a relatively specific pharma-
cologic Cdk inhibitor developed as a potential cancer
therapy [23] and previously shown to block cell cycle-
dependent apoptosis in cultured neurons [24].
Expressing tau in the retina (driver: GMR-GAL4), in-
cluding two forms of mutant tau (tauV337M and tauR406W),
results in degeneration of photoreceptor neurons and
gives a rough eye [17–19]. This phenotype consists of
a reduction in eye size and loss of regular ommatidial ar-
rangement (compare Figures 2M and 2N). We utilized
this phenotype to further examine genetic interactions
between tau-induced neurodegeneration and cell-cyclecomponents. From the two mutant forms of tau, we se-
lected a tauV337M line [25] that had a moderate rough eye
and was therefore a suitable substrate for genetic mod-
ification.
As with panneural expression (Figure 2B), coexpress-
ing bgal and Rbf1 with mutant tau did not substantially
ameliorate retinal toxicity (see Figure S1C in the Supple-
mental Data available with this article online). However,
coexpressing both Dap and Rbf1 (Figure 2O) or human
p21 and Rbf1 (not shown) significantly suppressed the
rough eye. Rescue was also achieved by coexpressing
Dap and Cdk1DN (Figure 2P) or Rbf1 and Cdk1DN (not
shown). A null allele, E2F191 (Figure 2Q), and two defi-
ciencies that uncover the E2F1 locus (not shown) domi-
nantly suppressed the phenotype, as did loss-of-func-
tion alleles of Cyclin B3 (CycB3L6540; Figure S1D) and
Cyclin A (CycAC8LR1; Figure 2R). Expression of Cdk4/
Cyclin D (Figure 2S), Cyclin B (Figure 2T), Cyclin A
(Figure 2U), Cyclin E (Figure S1F), Cdk1/Cyclin B (Fig-
ure S1H), and Cyclin B3 (not shown) markedly enhanced
the rough eye. Expression of these positive cell-cycle
regulators alone did not significantly alter the structure
of the eye (Figures S1E and S1G; not shown). Coexpres-
sion of Cdk1 or Cdk2 without their cyclin partners had no
effect (not shown). These data substantiate and extend
our finding in the brain that mutant tau-induced neuro-
degeneration is cell-cycle dependent.
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(A–D) Cell-cycle modulation modifies the tauWT-induced rough-eye phenotype. The tauWT-induced rough eye (A) is suppressed by coexpression
of Dap and Rbf1 (B) and enhanced by coexpression of either Cdk4/Cyclin D (C) or Cyclin A (D).
(E–H) Cell-cycle modulation modifies the pseudophosphorylated tauE14-induced rough-eye phenotype in which all Ser/Pro and Thr/Pro kinase
target sites are mutated to glutamate. The tauE14-induced rough eye (E) is suppressed by coexpression of Dap and Rbf1 (F) and enhanced by
coexpression of Cdk4/Cyclin D (G) or Cyclin E (H).
(I) Cell-cycle modifiers depicted in (A)–(D) do not alter levels of phosphoepitopes PHF1 (S396, S404), AT180 (T231, S235), or AT8 (S202, T205).
Blots were each reprobed with a phospho-independent antibody to tau (TAU) and actin (ACTIN), shown here for the AT8 experiment. Quantitation
fromR3 independent experiments indicated no statistically significant differences (one-way ANOVA with post hoc for multiple comparisons).
(J) At equivalent expression levels to tauWT, tauE14 induces significantly more apoptotic neurodegeneration in the brain accompanied by sub-
stantially higher numbers of PCNA-positive neurons (unpaired t test; ***p < 0.001; ****p < 0.0001; error bars: 6 SEM). Flies aged to 30 days.
(K) PH3 (green; nuclear stain) frequently colocalizes with AT8, PHF-1, and AT-180 (red; cytoplasmic stain) in the brains of mutant tauR406W-
expressing flies. All flies shown at 10 days.Cell-Cycle Modulation Modifies Wild-Type
Tau-Induced Neurodegeneration
AD and sporadic tauopathies are associated with abnor-
mal neuronal accumulation of wild-type tau (tauWT). Ex-
pressing tauWT is less toxic to neurons than express-
ing mutant tau [17], but also induces progressiveneurodegeneration in flies that is PCNA positive at 30
days (Figure 3J). Retinal expression of tauWT gives
a rough eye (Figure 3A; [18]), and we found that cell-cy-
cle modulators (Figures 3B–3D) modified this phenotype
as effectively as for mutant tau, indicating that tauWT-in-
duced neurotoxicity is also cell-cycle dependent.
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without Altering Phosphorylation at Key Serine
and Threonine Sites
Multiple lines of evidence implicate tau hyperphosphor-
ylation in neurodegeneration [1]. Since many disease-
associated phosphoepitopes are generated by phos-
phorylation at Ser-Pro and Thr-Pro motifs and Cdks
are proline-directed kinases, we tested whether cell-
cycle manipulations modified tau toxicity through alter-
ing tau phosphorylation.
Accumulation of abnormally hyperphosphorylated tau
and the presence of disease-associated phosphoepi-
topes accompanies tau-induced neurodegeneration
[17–19]. We focused on three disease-associated phos-
phoepitopes, AT8, PHF-1, and AT180, which can be cre-
ated by Cdks in vitro and during mitosis of cultured cells
[26]. We found that these epitopes accompanied retinal
(Figure 3I) and brain (Figure 3K; [17]) degeneration in our
tauopathy model. However, quantitation of at least three
separate experiments revealed no statistically signifi-
cant changes in any of these epitopes (AT8, p > 0.5;
PHF-1, p > 0.2; AT180, p > 0.8; one-way ANOVA with Stu-
dent-Neuman-Keuls post hoc) despite dramatic modifi-
cation of toxicity (Figures 3A–3D and 2).
Tau-Induced Cell-Cycle Activation Depends
upon Tau Phosphorylation
The inability of cell-cycle modulation to alter tau
phosphoepitopes (Figure 3I) raised the possibility that
cell-cycle activation might occur downstream of tau
phosphorylation. To test this, we first created a pseudo-
phosphorylated tau construct in which all 14 Ser-Pro and
Thr-Pro kinase target sites were mutated to glutamate
(tauE14). We found that, when expressed at equivalent
levels to tauWT, tauE14 not only induced enhanced toxic-
ity in the brain but also substantially more PCNA-positive
(Figure 3J) and PH3-positive (not shown) neurons, con-
sistent with cell-cycle activation being downstream of
tau phosphorylation. To further support this model,
tauE14-induced retinal toxicity (Figure 3F) was clearly
modified by cell-cycle manipulation (Figures 3E–3H), in-
dicating that cell-cycle modification of tau-dependent
neurotoxicity is not mediated through Ser-Pro/Thr-Pro
phosphorylation sites.
To substantiate the dependence of cell-cycle activa-
tion upon tau phosphorylation, we expressed tau in
the brain in a shaggy (sgg) loss-of-function genetic
background. Sgg is the fly homolog of glycogen syn-
thase kinase-3 (GSK-3), a Ser/Thr kinase and well-
established modifier of tau toxicity and phosphorylation
in flies [18]. Overexpressing sgg has previously been
shown to increase generation of the AT100 tau phos-
phoepitope [18, 19], and we found that AT100 levels
were reduced in a sgg mutant background (Figure S2A).
Importantly, this reduction was accompanied by a signif-
icantly fewer PCNA-positive neurons (Figure S2B).
These data, together with the tauE14 analysis (Figure 3J),
indicate that altering tau phosphorylation modulates
cell-cycle activation, while cell-cycle modifiers do not
change tau phosphorylation (Figure 3I).
Finally, we observed frequent colocalization between
PH3 and tau phosphoepitopes in tauR406W transgenic
flies (Figure 3K; driver: ELAV-GAL4) and used immuno-
histochemical methods to quantify this. In the centralbody complex, we quantified the number of PH3-posi-
tive cells (mean = 107.5/hemibrain; n R 6 hemibrains)
that were also tau phosphoepitope positive. We found
that the majority of PH3-positive neurons (>90%) were
also immunoreactive for AT8, PHF-1, or AT180, consis-
tent with tau phosphorylation preceding cell-cycle acti-
vation. In contrast, we found that approximately 90%,
50%, and 20% of neurons were immunoreactive for
AT8, PHF-1, and AT180, respectively, in a well-defined
area of the cortex, the caylx of the mushroom body (n =
8 hemibrains). These numbers were representative of
overall prevalence throughout the brain. Thus, the signif-
icant overlap of PH3 and disease-related phosphoepi-
topes did not occur by chance alone. Our biochemical,
genetic, and immunohistochemical data strongly sug-
gest that cell-cycle activation is dependent upon and
downstream of tau phosphorylation in our model.
Ectopic Cell-Cycle Activation Leads to Apoptotic
Neurodegeneration in the Adult Fly Brain
If cell cycle directly mediates apoptosis in our tau model,
then ectopic cell-cycle activation should lead to apopto-
tic neurodegeneration in the absence of transgenic tau.
We activated the cell cycle by ectopically expressing
positive regulators of the G1/S transition (Figure 2A). Ex-
pressing E2F1/DP in the brain with the ELAV-GAL4
driver is lethal. We therefore selectively induced E2F1/
DP expression in the adult fly brain (driver: ELAV-Gene-
Switch [27]). At 10 days, there was marked loss of cor-
tical neurons and rarefaction of the underlying neuropil
compared to controls (Figures 4A and 4B). Many neu-
rons were strongly immunolabeled with anti-PCNA
(Figure 4C) and anti-PH3 (Figure 4D) and were TUNEL
positive (Figure 4E). These markers were also observed
in the brains of Cyclin E-expressing flies (Figures 4F–
4H), while nontransgenic control flies were negative for
these markers (Figure 1; data not shown).
Thus, cell-cycle activation in postmitotic neurons
leads to neuronal apoptosis in vivo. The converse, how-
ever, is not true because direct induction of the proap-
totic gene reaper in adult neurons did not lead to cell-
cycle activation, despite dramatic induction of apoptosis
(Figures 4I and 4J).
The TOR Pathway Mediates Cell-Cycle Activation
and Tau-Induced Neurodegeneration
TOR activation drives growth and cell-cycle progression
in Drosophila [28, 29]. To investigate TOR signaling as
a possible upstream event in tau-mediated cell-cycle
activation, we first determined whether TOR activity
was increased in our model. We used an antibody spe-
cific for the activated form Drosophila S6k, phosphory-
lated at Thr398 (P-S6k). We found that expressing tau
in the brain induced a marked increase in P-S6k (Fig-
ure 5B). Interestingly, total S6k levels were decreased
in the brain when S6k activity was increased by either
tau or Rheb expression (Figure S4).
To determine whether blocking TOR activity pharma-
cologically or genetically could reduce mutant tau-in-
duced neurodegeneration in the brain, we first fed flies
rapamycin, a macrolide antibiotic that is a specific
TOR inhibitor [13]. Rapamycin treatment reduced the
number of TUNEL-positive cells (Figure 5C) and neuro-
degenerative vacuoles (not shown) by 10 days. We
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(A–E) Expression of E2F1-DP in the brain induces cell-cycle activation and neurodegeneration. The normal appearance of mushroom body cor-
tex (cx) and neuropil (n) in control fly is lost after expression of E2F1-DP, which induces cortical neuron loss and neuropil rarefaction (B). Neurons
are immunopositive for PCNA (C, arrow) and PH3 (D, arrow) and are TUNEL positive (E, arrows). All flies are aged to 10 days. Hematoxylin and
eosin staining is used in (A) and (B). Nuclear counterstain is used in (C) (hematoxylin; blue) and (E) (methyl green; green). Scale bar equals 10 mm.
(F–H) Expression of Cyclin E in the brain induces cell-cycle activation and neurodegeneration. Cyclin E induces PCNA expression (F, arrow), PH3
expression (G, arrow), and positive TUNEL staining (H, arrows) in neurons. Flies are aged to 10 days. Nuclear counterstain is used in (F) (hema-
toxylin; blue). Scale bar equals 10 mm.
(I and J) Cell-cycle activation does not accompany direct induction of apoptosis by reaper overexpression. 24 hr after induction of reaper, many
neurons are found to be TUNEL positive (I, arrows), but the brain is completely immunonegative for PCNA (J). Scale bar equals 10 mm.also coexpressed a transgenic Tsc2 construct lacking
inhibitory Akt phosphorylation sites (Tsc2DAKT; [30])
with tau and found a marked reduction in TUNEL stain-
ing (Figure 5D) and vacuolization (not shown). In addi-
tion, the tau-induced rough eye was dominantly sup-
pressed by Tsc2DAKT expression (Figure S3E) and by
Rheb, TOR, S6k, and eIF4e loss-of-function alleles (Fig-
ures S3F and S3G; not shown), an effect that could be
augmented by coexpressing Tsc transgenes or by re-
moving a single copy of Cdk4 (Figures S3H and S3I).
We conclude that both genetic and pharmacologic inhi-
bition of the TOR pathway rescues neurons from tau-
mediated toxicity.
To establish a requirement for TOR signaling in tau-in-
duced neurotoxicity, we overexpressed tau in a back-
ground null for specific TOR pathway components. A P
element insertion (fs(3)07084) has been described in
the 50 noncoding region of the S6k gene, the excision
of which results in a complete null allele with severe
growth restriction of homozygotes (S6kl-1; [31]). In flies
transheterozygous for the insertion and excision, S6k
activity (measured by P-S6k) was not detectable (not
shown) and tau toxicity was substantially reduced (Fig-
ure 5F). While flies null for TOR do not survive to adult-
hood, certain transheterozygous allelic combinations
are viable. Strikingly, tau toxicity was minimal in a ge-
netic background in which TOR activity was reduced
by approximately 75% (S.O., unpublished data; Fig-
ure 5G), and flies were obviously reduced in size (Fig-
ure S3B). These data indicate that TOR signaling is
required for tau-induced neurotoxicity.
While overexpressing TOR itself paradoxically down-
regulates TOR signaling [32], overexpressing Rheb ef-
fectively activates the pathway [28, 29]. Coexpression
of a Rheb transgene (RhebAV4; [29]) with tau strikingly
enhanced the tau-induced rough eye (Figure 6B). Ex-
pression of RhebAV4 alone gave an overgrowth pheno-
type with mild roughness (Figure S3C). TOR modulationsimilarly modified the tauWT-induced rough eye
(Figure S5).
To determine the mechanism of TOR-dependent
modification of tau toxicity, we first established that
TOR modulation did not alter tau levels or tau phosphor-
ylation (Figure 5H; data not shown). Notably, however,
Rheb-dependent enhancement of tau toxicity was
blocked by concomitant cell-cycle inhibition, either
dominantly by removing one copy of Cdk4 (Cdk43;
Figure 6C) or by coexpressing the cell-cycle inhibitors
Dap and Rbf1 (Figure 6D). Furthermore, when TOR
was ectopically activated in the fly brain, we found nu-
merous PCNA-, PH3-, and TUNEL-positive neurons (Fig-
ures 6E–6G). Thus, TOR activation can lead to cell-cycle
activation and apoptosis of postmitotic neurons in vivo.
Taken together, these results are consistent with TOR
signaling mediating tau-induced neurodegeneration
via cell-cycle activation.
Apoptosis in Several Tau-Independent
Neurodegeneration Models Is Cell Cycle
Independent
We investigated tau-independent models of apoptotic
neurodegeneration in flies to determine whether TOR-
dependent cell-cycle activation invariably drives neuro-
degeneration in vivo. Expression of a mutant polyglut-
amine protein MJD (Machado Joseph Disease) with an
expanded polyglutamine tract in the mushroom body
of the fly brain led to progressive loss of cortical neurons
and rarefaction of the neuropil (Figures 7A and 7B; [33,
34]). While neurodegeneration was apoptotic (Fig-
ure 7C), there were no PCNA-positive (Figure 7D) or
PH3-positive (not shown) neurons. Furthermore, TOR
and cell-cycle modifiers did not alter MJD-induced reti-
nal degeneration (Figures 7E–7I; [33]). Thus, TOR signal-
ing and cell-cycle activation do not mediate MJD-78-
dependent neurodegeneration in flies. Furthermore, we
found no evidence of cell-cycle activation in a fly model
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(A) In Drosophila, as in mammalian cells, TOR is activated by Rheb, which is negatively regulated by Tsc proteins. The downstream effectors of
TOR are eIF4e and S6k.
(B) An upregulation of S6k phosphorylation at T398 (P-S6k) is induced by panneural expression of tauR406W at 10 days. Phospho-S6kT398 appears
as a band at 70 kDa and is prominently upregulated in flies expressing UAS-Rheb. Driver: ELAV-GAL4.
(C and D) Neurodegeneration in the brain of 10-day-old flies, quantified by counting TUNEL-positive neurons, is suppressed by feeding flies the
TOR-specific inhibitor rapamycin (C) or by coexpressing a constitutively active Tsc2 transgene (D) (unpaired t test; *p < 0.05; **p < 0.01; error
bars: 6 SEM).
(E–G) TOR signaling is required for tauV337M-induced neurotoxicity. The tauV337M-induced rough eye (E) is prevented in backgrounds heteroallelic
for S6k (F) or TOR (G). Eye size reduction (F and G) is attributable to the substantial inhibition of growth in these genetic backgrounds (see
Figure S3B).
(H) Modulation of TOR signaling does not alter tau levels. Total tau levels shown for genotypes in (E)–(G).of Parkinson’s disease (PD; [35]), despite detecting
TUNEL-positive cells (not shown). These data indicate
that apoptotic neurodegeneration does not generally
occur via cell-cycle activation.
Discussion
Cell-Cycle Activation Causes Tau-Induced
Neurodegeneration
In this study we established a causal relationship be-
tween cell-cycle activation and tau-induced neurode-
generation in vivo. Expression of both mutant and
wild-type tau induced cell-cycle activation in our model
(Figures 1 and 3), and genetic inhibition of the cell cycle
substantially reduced tau-induced neurodegeneration
in both the fly brain and retina (Figures 2 and 3). The is-
sue of causality has previously been unresolved, al-
though important studies have documented aberrant
neuronal cell-cycle markers in human tauopathies and,
more recently, in a mouse tauopathy model [36]. Our
data also provide in vivo support for key experiments
in cell-culture systems that have demonstrated cell cy-
cle-dependent apoptosis in a variety of neurotoxic par-
adigms [4, 8, 24, 37, 38]. Previous reports have impli-
cated cell-cycle activation in rodent models of strokeand head trauma, although these studies have largely
relied upon pharmacologic inhibition of the cell cycle
by Cdk inhibitor drugs [39, 40]. Cdk inhibitors target sev-
eral non-cell-cycle kinase targets, including GSK-3 and
Cdk5 [23], that have also been implicated in cell survival
and tau phosphorylation. Indeed, while Cdk inhibitors
were recently shown to be neuroprotective in a toxic
mouse model of PD, this effect was found to be more at-
tributable to inhibition of Cdk5 than to inhibition of cell
cycle-related kinases [41].
In this study, we demonstrated PCNA-, PH3-, and
TUNEL-positive neurons in our tauopathy model (Fig-
ure 1) and concluded that cell-cycle activation and
apoptosis accompanied neurodegeneration. While ex-
pression of PCNA and PH3 have been described in pro-
cesses other than cell division (DNA repair and immedi-
ate early gene responses, respectively), our genetic data
implicating multiple components of the cell cycle in tau-
induced neurodegeneration strongly support a cell-
cycle role in our model. While TUNEL-positive cell death
may not always be apoptotic, previous reports showing
that antiapoptotic genes, including IAP-1, block tau-
induced neurodegeneration in flies [18, 25] support a
role for apoptosis in this model. The role of apoptosis
in tauopathies and animal tauopathy models remains
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237Figure 6. TOR Signaling Links Tau to Cell-Cycle Activation
(A–D) TOR activation enhances tau-induced neurotoxicity in a cell cycle-dependent manner. Rheb coexpression (B) enhances the tau-induced
rough eye (A). This enhancement is blocked by concomitant cell-cycle inhibition, either by removing one copy ofCdk4 (C) or by coexpressing Dap
and Rbf1 (D).
(E–G) Expression of Rheb in the brain induces cell-cycle activation and neurodegeneration. Rheb induces PCNA expression (E, arrow), PH3 ex-
pression (F, arrow), and positive TUNEL staining (G, arrows) in neurons. Flies are aged to 30 days. Scale bar equals 10 mm.
(H) A model for cell-cycle activation in tau-mediated neurodegeneration suggested by our data. Cell-cycle activation occurs downstream of tau
phosphorylation and upstream of apoptosis, and TOR links tau to the cell cycle.controversial, however. Recently, both apoptotic and
nonapoptotic neurodegeneration were described in
a mouse tauopathy model [36], and we cannot rule out
the possibility that nonapoptotic forms of cell death
occur in the fly model also.
Cell-Cycle Activation Is Downstream of Tau
Phosphorylation and Directly Leads to Apoptosis
The relationship between cell-cycle activation and tau
phosphorylation has previously been unclear. SinceCdks are proline-directed kinases known to phosphory-
late tau in vitro, cell-cycle activation could mediate neu-
rodegeneration by directly phosphorylating tau. Indeed,
several serine and threonine residues of tau are sub-
strates for Cdks in vitro, and mitosis in cultured prolifer-
ating cells is associated with tau phosphorylation at
these sites [26]. Second, cell-cycle activation could be
downstream of phosphorylation and directly lead to ap-
optosis in two plausible ways. First, forcing differenti-
ated cells to enter a cell cycle could directly lead toFigure 7. TOR-Mediated Cell-Cycle Activation Does Not Mediate MJD-Induced Neurodegeneration
(A–D) Expression of MJD-78Q in the brain induces apoptotic neurodegeneration in the absence of cell-cycle activation. The normal appearance
of mushroom body cortex (cx) and neuropil (n) in control fly ([A]; genotype: 30Y-GAL4/+) is altered by expressing MJD-78Q (B–D), which induces
cortical neuron loss and neuropil rarefaction (B). Neurons are TUNEL positive (C, arrows) but are completely negative for PCNA (D). A blue (he-
matoxylin) nuclear counterstain is used in (D). Scale bars equal 10 mm.
(E–I) Cell-cycle or TOR pathway manipulation does not alter the MJD-78Q-dependent rough eye. Normal eye pigmentation and external morphol-
ogy (E) is disrupted by expression of MJD-78Q (F). Coexpression of RhebAV4 (G), Tsc2DAkt (H), or Dap and Rbf1 (I), modifiers that strongly modify
the tau-induced rough eye, do not modify the MJD-78Q-induced rough eye.
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238apoptosis via an aborted attempt to replicate damaged
DNA. Such a mechanism may be particularly relevant to
postmitotic neurons that are known to have a limited ca-
pability for DNA repair [42]. Alternatively, it is possible
that cell-cycle mediators, including E2F1 and Cdk1,
may subserve dual functions as direct mediators of neu-
ronal apoptosis [37, 43].
Our data support a role for cell-cycle activation down-
stream of tau phosphorylation and directly preceding
apoptosis. First, cell-cycle markers often immunolocal-
ized to areas characterized histologically by nuclear
fragmentation and condensation (Figure 1F), suggesting
a late role in neurodegeneration. Second, cell-cycle
modulation dramatically modified tau-induced neurode-
generation without altering tau phosphorylation at dis-
ease-associated epitopes that can be generated by
Cdks in vitro (Figure 3I). In contrast, pseudophosphory-
lation of tau (Figure 3J) or reducing tau phosphorylation
in a sgg mutant background (Figure S2) directly in-
creased and decreased cell-cycle activation, respec-
tively. Third, cell-cycle modulation could still enhance
toxicity of tauE14, a pseudophosphorylated construct
in which all Ser-Pro and Thr-Pro target sites are mutated
to glutamate (Figures 3E–3H). Fourth, double labeling of
brains of tau-expressing flies for PH3 and tau phosphoe-
pitopes (Figure 3K) revealed that >90% PH3-positive
neurons were phosphoepitope positive, even for rela-
tively restricted epitopes such as AT-180 (20% of all
neurons). Finally, we showed that cell-cycle activation,
in the absence of transgenic tau, could directly lead to
apoptosis of postmitotic neurons in vivo (Figures 4A–
4H), supporting the possibility that cell-cycle activation
could directly transduce tau-induced apoptosis.
TOR Signaling Mediates Tau-Induced
Neurodegeneration via Cell-Cycle Activation
The mechanisms through which cell cycle becomes ac-
tivated in tauopathies have not been defined. Markers
that could represent aberrant mitogenic signaling are
aberrantly expressed in these diseases, including
markers of MAP kinase activation [44], classic onco-
genic pathways such as Src [45] and c-Myc [46], and
TOR activation [10–12]. However, the expression of iso-
lated markers, while interesting, establishes neither the
importance of a particular pathway as a whole nor
whether any of these pathways are able to reactivate
cell cycle in postmitotic neurons or lead to neurodegen-
eration in vivo. In this study, we showed that TOR activa-
tion occurred in our tauopathy model (Figure 5B),
recapitulating a similar finding in AD [10], and was fur-
thermore required for neurodegeneration (Figures 5C–
5G). Since TOR-dependent enhancement of tau toxicity
was blocked by concomitant cell-cycle inhibition, and
ectopic TOR activation led to neuronal cell-cycle activa-
tion and apoptosis in the adult fly brain (Figure 6), our
data indicate that TOR signaling mediates tau-induced
neurodegeneration via cell-cycle activation. The rela-
tionship between tau, TOR, and cell-cycle activation,
however, may be complex. In the retina, for example,
TOR activation in the absence of transgenic tau results
in an enlarged eye, whereas tau expression results in
a small, rough eye. It is plausible that these phenotypic
differences may be related to tau-induced pathogenic
events that occur upstream of TOR activation in ourmodel. Also, while our data strongly link TOR to cell-
cycle activation in our model, other TOR-dependent
mechanisms of neurotoxicity cannot be ruled out. For
example, TOR activation could theoretically enhance
neurodegeneration by inhibiting autophagy, although
the rescue of tau toxicity by loss of S6k (Figure 5F) would
argue against this possibility since S6k is an activator of
autophagy in flies [47].
Aging is a significant risk factor for tauopathies. Inter-
estingly, TOR inhibition is known to prolong lifespan in
Drosophila [14], and our data thus directly link an ag-
ing-related signal transduction pathway to tau-induced
neurodegeneration. Furthermore, withdrawal of amino
acids in vitro or starvation in vivo results in inhibition of
TOR signaling [13], potentially offering a molecular
mechanism for the neuroprotection reported in human
studies by caloric restriction [48].
Cell-Cycle ActivationMayBeSpecific to Tau-Induced
Neurodegeneration
In this study, we investigated the role of cell-cycle acti-
vation in tau-mediated neurodegeneration because ab-
errant expression of cell-cycle markers is best de-
scribed for tauopathies and AD. For example, one
comprehensive study found upregulation of cell-cycle
markers in AD and in a cohort of sporadic and inherited
tauopathies but not in other diseases including PD,
Huntington’s disease, amyotrophic lateral sclerosis
(ALS), or multiinfarct dementia [3]. However, others have
reported cell-cycle marker upregulation in the context of
spinal cord injury, ALS, and PD [8]. In addition, neuronal
expression of cell-cycle markers has been described in
several cell-culture paradigms of neurotoxicity (see
above) and in mouse models of ataxia [49, 50], leading
to the speculation that cell-cycle activation might be
a universal mechanism for neurodegeneration, perhaps
related to oxidative stress [8, 50]. In our study, however,
we did not find evidence of cell-cycle activation in fly
models of either MJD (Figure 7) or PD (not shown), de-
spite the presence of apoptotic neurodegeneration,
and cell-cycle modulation did not modify MJD-induced
neurodegeneration (Figure 7). These data implicate dis-
tinct mechanisms for neurodegeneration in different
neurodegenerative diseases, consistent with recent
findings that forward genetic screen modifiers differ be-
tween polyglutamine-, synuclein-, and tau-induced neu-
rodegeneration [51, 52].
In summary, our results indicate a common effector
pathway and potentially common therapeutic strategies
for cancer and tauopathy, two major causes of age-re-
lated morbidity and mortality. We delineate the TOR sig-
naling pathway, a known regulator of lifespan, as a re-
quired mediator of tau-dependent neurodegeneration
in vivo. Our results provide a rationale for the assess-
ment of TOR and cell-cycle inhibitors as potential thera-
peutic strategies in tauopathies and AD.
Experimental Procedures
Fly Stocks, Genetics
All fly crosses and experiments were performed at 25ºC. Flies were
age and sex matched in assessing modification of brain and eye tox-
icity. The human wild-type and mutant tau transgenic flies were pre-
viously described [17]. TOR2L7 and TOR2L15 will be described in de-
tail elsewhere (hypomorphic missense alleles; S.O., submitted).
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tauE14. The codons for T111, T153, S175, T181, S199, S202, T205,
T212, T217, T231, S235, S396, S404, and S422 were mutated to glu-
tamate (GAA or GAG) with the QuikChange site-directed mutagene-
sis kit (Stratagene), and the resulting pBS-htau24E14 was subcloned
into the pUAST vector to generate UAS-tauE14. Lines with expres-
sion level equivalent to tauWT were determined by quantitative West-
ern blot.
Drivers used were ELAV-GAL4 (panneural), GMR-GAL4 (retinal).
30Y-GAL4 (mushroom body) and ELAV-GeneSwitch (panneural, in-
ducible [27]). Flies were obtained from the Bloomington Drosophila
Stock Center (ELAV-GAL4, GMR-GAL4, UAS-rpr, CycB3L6540,
CycAC8LR1, Cdk43, eIF4e07238, S6k07084, S6kl-1, TORk17004,
Df(E2F1)(3R)e-BS2, Df(E2F1)(3R)e-N19/TM2, E2F107172, sgg1) or were gen-
erous gifts from N. Bonini (UAS-MJD-78Q), W. Cha (UAS-Cdk1E51Q
[22]), W. Du (UAS-Rbf280), N. Dyson (UAS-E2F1, UAS-DP, UAS-
Rbf1), P. Gallant (UAS-Rheb1.1), E. Hafen (Rheb2D1), I.K. Hariharan
(UAS-dap [21], UAS-p21, UAS-Tsc1, UAS-Tsc2), K. Kaiser (30Y-
GAL4), H. Keshishian (ELAV-GeneSwitch), C. Lehner (UAS-Cdk1,
UAS-Cdk2, UAS-Cdk4, UAS-CycA, UAS-CycB, UAS-CycD), T. Orr-
Weaver (E2F91), F. Tamanoi (RhebAV4 [29]), and T. Xu (UAS-Tsc1,
UAS-Tsc2DAkt). Note that Cdk1 is identical to cdc2.
Complete genotypes can be found in the Supplemental Data.
Sectioning, Immunostaining, and Histology
Adult flies were fixed in formalin at 1 or 10 days and embedded
in paraffin. Serial frontal 4 mm sections including the entire brain
were prepared. Antigen retrieval was performed by microwaving in
sodium citrate buffer. Immunostaining was performed with an avi-
din-biotin-peroxidase complex (ABC) method (Vector Laboratories)
or with secondary antibodies coupled to Alexa Fluor 488 or Alexa
Fluor 555. For quantification of PH3/tau phosphoepitope double la-
beling, alkaline phosphatase-conjugated secondary antibodies
were used and histochemical detection performed with Vector
Red (Vector Laboratories) and DAB. Primary antibodies included
anti-PCNA (1:500; Biomeda), -PH3 (1:500; Upstate), -AT8 (1:1000; In-
nogenetics), -PHF-1 (1:200; a generous gift from P. Davies), and
-AT180 (1:500; Innogenetics). Secondary antibodies were used at
1:200 dilution. Where noted in the figures, nuclei were counter-
stained with hematoxylin. To assess morphology, sections were
stained with hematoxylin and eosin under a standard protocol. For
PCNA quantification (Figure 3; Figure S2), at least four brains were
used per genotype and the number of PCNA-positive neurons/neu-
ronal clusters were summed across the whole brain. Statistical sig-
nificance was established as for TUNEL staining (see below). We as-
sessed PH3/tau phosphoepitope colocalization (p10) in 10 frontal
sections through the central body complex from at least 6 hemi-
brains. The overall prevalence of tau phosphoepitopes was quanti-
fied in the calyx of the mushroom body in 8 hemisections (4 separate
brains; average of 135 cells/hemisection).
TUNEL Staining
Neuronal apoptosis was detected with the TUNEL assay with a com-
mercially available kit (TdT FragEl, Oncogene). Where noted, nuclei
were counterstained with methyl green. Neurodegeneration was
quantified in 10-day-old (Figures 2 and 5) or 30-day-old (Figure 3)
flies by counting the number of TUNEL-positive cells per hemibrain
in consecutive frontal sections between the ellipsoid body anteriorly
and the mushroom body posteriorly. At least eight hemibrains were
examined per time point for each genotype. Statistical significance
was established by one-way ANOVA with post hoc test for multiple
comparisons (Student-Neuman-Keuls; *p < 0.05; **p < 0.01; ***p <
0.001). An unpaired t test was used for the single comparison in
the tauE14, rapamycin, Tsc2DAKT, and Sgg experiments (Figures 3K,
5C, and 5D and Figure S2, respectively; *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001).
Western Blot
Heads from adult flies at 1 day posteclosion were homogenized,
separated by SDS-PAGE, and immunoblotted with one of the follow-
ing antibodies: anti-tau (Dako; 1:1 million); monoclonal antibodies to
AT8, AT180, PHF-1 as described above at 1:100,000, 1:1,000, and
1:100,000, respectively; anti-AT100 (Innogenetics; 1:1000); anti-
phosphoS6kT398 (Drosophila-specific; Cell Signaling; 1:1000); anti-total S6K (C-terminal monoclonal; 1:500; a generous gift from G.
Thomas); or anti-actin (20-66; Sigma; 1:50,000). The appropriate
secondary antibody was applied at 1:50,000 diultion and signals
were detected by chemiluminescence (Pierce). Boiling (5 min,
PBS) was used for antigen retrieval prior to blocking in the case of
AT180 and AT100. At least three separate experiments were used
for quantitation by ImageJ (NIH). For Figure 3I, one-way ANOVA
with Student-Neuman-Keuls post hoc test for multiple comparisons
was used to test for statistically significant differences.
Drug Feeding
Olomoucine
1, 5, or 10 mM olomoucine (Sigma) in 10% DMSO was mixed in
a yeast paste and fed to flies for 10 days after eclosion. Food was
changed every second day. Control flies were fed 10% DMSO alone.
See Figure 2.
RU486
For induction of E2F1-DP expression with the RU486-inducible
ELAV-GeneSwitch driver (Figure 4; [27]), we fed flies RU486 (10
mg/ml; Sigma) for 10 days after eclosion in instant Drosophila me-
dium (Carolina). Controls were fed the same concentration of drug
for 10 days. For reaper induction, we fed 1-day-old flies RU486 for
24 hr. Control flies were drug-free 1-day-old flies of the same geno-
type.
Rapamycin
2.5 mM rapamycin (Sigma) in 2.5% DMSO was mixed in a yeast
paste and fed to flies for 10 days after eclosion. Control flies were
fed 2.5% DMSO alone. Food was changed every second day. See
Figure 5.
Supplemental Data
Supplemental Data include five figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.current-biology.com/cgi/content/full/16/3/230/DC1/.
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